drugset / Trial / NCT05447208

Effect of GH on the Blastocyst Euploid Rate in AMA Patients

NCT05447208

Phase 3 Recruiting 400 enrolled ShangHai Ji Ai Genetics & IVF Institute
RandomizedParallel-groupSingle-blindTreatment

Summary

This randomized trial aims to compare the euploid rate of blastocysts in AMA patients undergoing PGT-A (preimplantation genetic testing for aneuploidy) with or without growth hormone supplement. Infertile patients ≥38 years old will be recruited for study after informed consent if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups: Treatment group: Women will receive growth hormone (GH) supplement before and during antagonist protocol for ovarian stimulation. Control group: Women will receive antagonist protocol for ovarian stimulation. The primary outcome is the euploidy rate of blastocysts.

Timeline

Start
2022-08-01
Primary completion
2026-03-01
Completion
2026-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 2 iu Subcutaneous
Background Cetrorelix Other / unclassified 0.25 mg Subcutaneous

Indications

No indication recorded.